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Abstract 
Pentacycloundecylamine (PCU) derived compounds have been shown to be 
promising lead structures for the development of novel drug candidates aimed at a 
variety of neurodegenerative and psychiatric diseases. Here we show for the ﬁrst 
time a 3D quantitative structure–activity relationship (3D-QSAR) for a series of 
aza-PCU-derived compounds with activity at the sigma-1 (r1) receptor. A 
comparative molecular ﬁeld analysis (CoMFA) model was developed with a partial 
least squares cross validated (q2) regression value of 0.6, and a non-cross validated
r2 of 0.9. The CoMFA model was effective at predicting the sigma-1 activities of a
test set with an r2 >0.7. We also describe here the docking of the PCU-derived
compounds into a homology model of the sigma-1 (r1) receptor, which was 
developed to gain insight into binding of these cage compounds to the receptor. 
Based on docking studies we evaluated in a [3H]pentazocine   binding   assay   an
oxa-PCU,   NGP1-01   (IC50 = 1.78 lM)   and   its   phenethyl   derivative (IC50 = 
1.54 lM). Results from these studies can be used to develop new compounds with 
speciﬁc afﬁnity for the sigma-1(r1) 
Sigma receptors were initially thought to belong to the opiate receptor family, but were 
later shown to better associate with another unique family of small proteins.1 These
receptors  are now divided into two subtypes denoted as sigma-1 (r1) and sigma-2 
(r2).2,3 These relatively small receptors act as chaperone molecules where, upon
agonist activation, they are able to translocate from the endoplasmic reticulum (ER) to 
the cell membrane.4 The two main sigma receptors were found to differ in size, the
sigma-1 receptor being a rv29 kDa single polypeptide5 and the sigma-2 receptor
ranging in size between 18 and 21.5 kDa.6 Additionally, the sigma-1 receptor has been
cloned, whereas the sigma-2 receptor has not been cloned to date.5,6 The sigma
receptor signaling pathway still remains to be fully elucidated but current literature 
suggests that the sigma receptor protein plays a role in cellular stress by modulation of 
calcium ﬂux in the ER as well as mitochondria.7,4,8,9 Recently, it has been shown in
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sigma-1 receptor knock-out mice that the mice showed signs of accelerated retinal 
ganglion cell death, suggesting that sigma receptor ligands may have possible utility 
in preventing the  neurodegeneration seen in glaucoma.10 These ﬁndings corroborate 
previous work which suggested that (+)-pentazocine afforded neuroprotection against 
retinal neurodegeneration via sigma-1 receptors.11 
 
In the late 1990s, it was shown that pentacycloundecylamine-derived compounds 
(PCUs) exhibit afﬁnity for the sigma-1 and sigma-2 receptors. This class of polycyclic 
cage compounds also was shown to display selectivity between the two sigma 
receptors.12 Furthermore, pentacycloundecylamine-derived compounds have been 
shown to have functional activity on the sigma receptor system, such as enhancing the 
dopamine releasing effect of amphetamine13 as well as methamphetamine,14 and also 
were able to modulate addiction behavior with cocaine via sigma receptor 
modulation.15 Binding studies have shown that for sigma-1 receptor binding, an ethyl-
linker is needed between the aza-bridgehead and the aromatic ring, whereas for 
sigma-2, a benzyl moiety is more favorable.16 Additionally, meta-substitution on the 
aromatic ring favors increased afﬁnity for both of these receptors, with the halogen 
ﬂuorine appearing to afford optimal activity.16 
 
In our efforts to develop neuroprotective compounds in glaucoma, we focused on 
gaining insight into the structure–activity relationships of the PCU compounds at the 
sigma-1 receptor. To date, no 3D quantitative structure–activity relationship (3D-
QSAR) studies have been published for pentacycloundecylamine-derived compounds. 
The current study aims to elucidate the steric and electrostatic features for binding 
to sigma-1 receptors, which may aid medicinal chemists to design and optimize 
pentacycloundecylamine-derived compounds as sigma ligands. 3D-QSAR modeling was 
done using the CoMFA modules of SYB-YL 8.1 (Tripos, St. Louis, MO), running on a Dell 
XPS720 3.66 GHz PC dual  booted  to  run  Red  Hat  Linux  Enterprise  5  and  Microsoft 
Windows  XP.  Compound  alignment  for  CoMFA  was  performed using the software suite 
from Openeye (Santa Fe, NM, USA). Compounds were drawn in SYBYL, and exported as 
SDF ﬁles. The SDF ﬁles were then used by OMEGA 2.3.2 (OpenEye Scientiﬁc Software, Santa 
Fe, NM, http://www.eyesopen.com) which generates multiple conformers of each 
compound. ROCS 2.4.1 (OpenEye Scientiﬁc Software,  Santa  Fe,  NM,  
http://www.eyesopen.com)  (commandline mode) software from Openeye using the RANKBY 
COMBO ﬂags which  optimize  both  shape  overlay  and  chemical  (color)  overlay.27,28  
Compound 5  was used as query. The resulting overlay of compounds shown in Table 1 was 
then used for the CoMFA analysis. The aligned compounds (Fig. 1) from ROCS were used 
for the study. Gasteiger–Hückel charges were added before the CoMFA calculation. The 
compounds used to develop the CoMFA model were divided into a training set and a test set 
using the QSAR Wizard program for MOE, available for download at the Chemical 
Computing group  SVL  exchange  (http://svl.chemcomp.com/).  The  complete set was 
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randomly divided irrespective of activity or chemical composition, so that an 80% 
separation could be achieved.23 
 
Default values provided in the Tripos CoMFA module were used with a 2.0 Å grid spacing 
using an sp3 carbon atom with a +1 point charge as a probe to explore the steric and 
electrostatic interactions at the lattice points in the grid. The default cut-off value was 
set at 30 kcal/mol. Statistical analysis was performed using the partial least squares 
method implemented in the SYBYL program. Non-cross validated (r2) values were 
determined for the models using linear regression analysis (with variances reported as the 
standard error of estimation, SEE) which is considered signiﬁcant when r2 is greater than 
0.7. The q2 values obtained were considered signiﬁcant at 0.3. The 3D graphical 
representation of the steric and electrostatic ﬁelds generated through CoMFA is shown with 
the relative contributions of these ﬁelds represented as a 3D coefﬁcient map with favored 
80% steric (green) and electro-static (blue) effects and 20% disfavored steric (yellow) and 
electro-static effects (red). Green colored areas of the map indicate where sterically bulky 
groups may enhance interaction afﬁnity. Blue colored areas (80%) indicate regions where a 
more positively charged group will likely lead to increased binding afﬁnity, while red areas 
indicate where a more negatively charged group will likely lead to increased binding (20%). 
Biological data were taken from the literature12,15–18 and entered as pKi values in the 
spreadsheets accessed by the CoMFA routine in SYBYL (Table 1). 
 
The results from the CoMFA study are shown in Figure 2 and summarized in Table 2. 
This model gave a good cross-validated regression (q2) of 0.6 for the training set 
compounds. Statistically signiﬁcant models usually are expected to yield q2                           
xcess of 0.3. The non-cross validated regression of the CoMFA model was found to be 0.9 
(Table 3). In this model, electrostatic contributions played a more signiﬁcant role than steric 
contributions, with contributions of 61% and 39%, respectively. 
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This is to be expected, since the aromatic substitution pattern in the training set heavily 
favored halogens that all inﬂuence the electronic character of the aromatic ring. To validate 
the CoMFA model, the activities of the test set compounds were predicted (Table 4). The 
CoMFA model was able to predict the activities of the test set compounds with an r2  of 
0.78, suggesting the model to be reliable also in predicting other similar cage compounds’ 
activity at the sigma-1 receptor (Fig. 3). 
 
The contour maps of the CoMFA model with compound 5 are shown in Figure 2. As can 
be seen from this ﬁgure, the contour maps correlate with the steric (39%) and electrostatic 
(61%) contributions calculated in the CoMFA model. Green maps indicate areas where 
increased bulk (i.e., adding larger groups) to the molecule would likely lead to an increase 
in activity, while the yellow areas indicate areas that are sterically hindered, that is where 
increasing steric bulk would likely lead to a decrease in activity. Two green maps can be 
seen, with a larger map located in close proximity to the aromatic ring of the compounds 
and a smaller map located near the C1–C2 chain between the cage-amine and the 
aromatic ring. A large yellow map is located close to the green map. Taking these steric 
maps into consideration, it is clear that the substitution pattern on the aromatic ring 
signiﬁcantly inﬂuences the activity of these compounds. 
  
http://repository.uwc.ac.za
6 
 
 
http://repository.uwc.ac.za
7 
 
 
 
Even though CoMFA maps should not be over interpreted as ‘receptor’ maps, it may 
suggest that the substituents are generally interacting with a speciﬁc grouping of 
amino acid residues in the sigma-1 receptor, and that larger groups in this region are 
likely to decrease interaction. Electrostatic maps are shown in red and blue, indicating 
http://repository.uwc.ac.za
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areas where negative and positive charges respectively, would likely increase activity. 
These aza-cage amines all share an oxygen moiety near the aza-bridge head. For 
example in compound 5, and seen in Figure 2, a large red map surrounds these 
oxygen atoms, while two smaller red maps are located close to the aromatic ring (e.g., 
compound 5), correlating with substituent positions. The blue map correlates with the 
aza nitrogen of the compounds, and supports the observation that compounds without 
the aza-bridge have limited or no activity for the sigma-1 receptor.16 
 
For compounds 20 and 23, which are the most potent binders to sigma-1 receptor 
compounds in this series, it can be seen that their respective aromatic rings are 
oriented towards the green contour, which would indicate an increased activity (Fig. 
2). In contrast to this, in the same series compounds 15 and 16 exhibit the lowest 
afﬁnity for binding to the sigma-1 receptor, which could be explained by the 
projection of the NO2- and CF3-groups into the large yellow sterically disfavored area. 
Additionally, for compound 16, the oxygen atoms of the NO2- group extend towards a 
blue map that could also explain its lack of activity at the sigma-1 receptor. The activity 
of compounds 4 and 24 can also be explained by the CoMFA model by the fact that 
the carbon-chain connecting the cage with the aromatic ring extends towards a green 
map. 
 
To gain insight into the interaction between this series of pentacycloundecylamine-
derived compounds and the sigma-1 receptor, we developed a homology model. 
Homology modeling was done using YASARA structure version 10.10.4.19,20 We 
chose to use YASARA based on its impressive performance at CASP8, an 
international competition for the prediction of protein structure (see Ref. 21 for 
further information on the methodology of how YASARA performed at CASP8, as well 
as the methods of homology modeling,20 and also at YASARA’s website: 
www.yasara.org). The resultant homology model was based on the template structure 
recently reported.22 The receptor homology was based on protein code 3CIA. For the 
docking study, we used MOE-Dock (www.chemcomp.com). The protein was 
protonated at pH 7.4, to assure biological relevance. As can be seen in Figure 4, the 
pentacycloundecylamines docked into two distinct, but closely proximal sites (Fig. 
4A). A pocket deeper into the protein, as well as one closer to the surface is evident. 
Docking studies suggest that for compound 19 (Ki = 20 nM), the aromatic ring is able 
to orient towards the inner part of the receptor (Fig. 4B) for possible hydrophobic 
interactions. This orientation is in contrast with data found for compound 16 (Ki = 
1100 nM), where the –NO2 moiety is oriented towards the solvent interface (Fig. 4C), 
leaving only the cage unit and possibly the secondary amine and hydroxyl groups to 
undergo hydrogen bonding. As seen from Figure 4D, compound 18 shows a probable 
hydrogen bonding opportunity between the secondary amine,  hydroxyl  and  MET1,  
indicating  that  this  binding  mode may play a role in activity. To validate that the 
aza nitrogen is important in binding as shown in the docking study, we tested two 
http://repository.uwc.ac.za
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oxa-PCU-derived compounds, NGP1-01 and its phenethyl derivative23,24 for [3H]-
pentazocine binding in rat  liver  homogenate (Fig. 5).  As can be seen from the 
binding  data, there is a >10-fold decrease in activity for the binding of the oxa 
compounds as compared to the aza compounds. Taken together with the docking data, 
this suggests that the aza orientation is be generally preferred for binding to the sigma-
1 receptor. The importance of the nitrogen in binding to the sigma-1 receptor 
corroborates in part previous pharmacophore work published, which suggested that 
at a minimum, one nitrogen was important for binding of phenylalkylpiperidines and 
phenylalkylpiperazines. A previous pharmacophore for the sigma-receptor was suggested 
to be C-N(R)-X-Ph. Additionally, the C and aromatic moiety (Ph) from the 
pharmacophore are located in areas of bulky hydrophobic tolerance.25 This presence 
of two hydrophobic pockets may accommodate several binding modes for a single 
compound.25,26  From the current study, it can be extrapolated that the polycyclic cage 
may prove useful in future studies to delineate binding to these two hydrophobic 
pockets, and therefore binding modes, as compared to the use of only aromatic rings 
as seen in many of the compounds published. 
 
In conclusion, in this study, we have shown a 3D-QSAR model for 
azapentacycloundecylamine-derived compounds at the sigma-1 receptor. The conclusion 
from this model is that the substitution pattern on the aromatic ring has a low 
tolerance for sterically large groups, with the electrostatic nature of the substituent 
further determining binding in these structures. 
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Here too we show docking data, where two main clusters of docked compounds in a 
putative binding site are shown. With the pentacycloundecylamine-derived compounds 
showing promise as lead structures in a variety of psychiatric and neurodegenerative 
diseases, the current model could be used to develop novel compounds within this 
class. 
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